Trexquant Investment LP Acquires 167,631 Shares of AMNEAL PHARMACEUTICALS, INC. $AMRX

Key Points

• Trexquant Investment LP increased its stake in AMNEAL PHARMACEUTICALS by 36.2%, owning 630,351 shares valued at approximately $5.28 million as of the latest reporting period.
• Several other hedge funds have also increased their positions in AMNEAL PHARMACEUTICALS, with notable increases from Janney Montgomery Scott LLC and Allspring Global Investments.
• Analysts currently have a consensus rating of "Buy" for AMNEAL PHARMACEUTICALS, with a target price of $11.60, following recent coverage by the Goldman Sachs Group.

Trexquant Investment LP lifted its holdings in AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Free Report) by 36.2% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 630,351 shares of the company's stock after acquiring an additional 167,631 shares during the quarter. Trexquant Investment LP owned 0.20% of AMNEAL PHARMACEUTICALS worth $5,282,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. GAMMA Investing LLC raised its holdings in AMNEAL PHARMACEUTICALS by 5,975.0% during the 1st quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock valued at $26,000 after buying an additional 3,107 shares during the last quarter. Headlands Technologies LLC purchased a new position in AMNEAL PHARMACEUTICALS during the 1st quarter valued at $31,000. Amalgamated Bank grew its position in shares of AMNEAL PHARMACEUTICALS by 33.0% in the 1st quarter. Amalgamated Bank now owns 5,511 shares of the company's stock worth $46,000 after buying an additional 1,367 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of AMNEAL PHARMACEUTICALS in the 4th quarter worth about $52,000. Finally, Brevan Howard Capital Management LP purchased a new stake in shares of AMNEAL PHARMACEUTICALS in the 4th quarter worth about $107,000. 31.82% of the stock is currently owned by institutional investors.

Insider Buying and Selling at AMNEAL PHARMACEUTICALS

In related news, Director John Kiely sold 32,000 shares of the firm's stock in a transaction on Wednesday, August 27th. The stock was sold at an average price of $9.23, for a total value of $295,360.00. Following the completion of the sale, the director directly owned 225,433 shares in the company, valued at $2,080,746.59. This trade represents a 12.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jason B. Daly sold 22,000 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $9.05, for a total value of $199,100.00. Following the completion of the sale, the executive vice president owned 10,606 shares of the company's stock, valued at approximately $95,984.30. This represents a 67.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 609,206 shares of company stock valued at $5,700,625. 26.56% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on AMRX. The Goldman Sachs Group began coverage on shares of AMNEAL PHARMACEUTICALS in a research report on Friday, June 6th. They set a "buy" rating and a $12.00 price objective on the stock. Wall Street Zen cut shares of AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $11.60.

AMNEAL PHARMACEUTICALS Stock Performance

AMRX traded up $0.07 during trading on Friday, reaching $9.62. 1,273,897 shares of the company traded hands, compared to its average volume of 1,583,692. AMNEAL PHARMACEUTICALS, INC. has a 12-month low of $6.68 and a 12-month high of $9.79. The firm has a fifty day simple moving average of $8.67 and a 200 day simple moving average of $8.13. The company has a market cap of $3.02 billion, a P/E ratio of 962.96 and a beta of 1.19.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a net margin of 0.12% and a negative return on equity of 189.49%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, sell-side analysts expect that AMNEAL PHARMACEUTICALS, INC. will post 0.53 earnings per share for the current fiscal year.

AMNEAL PHARMACEUTICALS Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.